PharmAbs is a KU Leuven innovation, valorisation and incubation platform for the development of antibody-based therapeutics and diagnostics. PharmAbs’ expertise and technologies are used to translate basic scientific innovations emerging at universities into diagnostic/therapeutic solutions for personalized medicine that can be implemented in the clinic and/or commercialized by third parties.

PharmAbs offers antibody solutions to academic groups and companies. Read more.

Technology offers and licensing opportunities. Read more

PharmAbs established a structural collaboration with KU Leuven MeBios to develop integrated diagnostics and life science research tools.

Follow PharmAbs on LinkedIn   Afbeeldingsresultaat voor linked in


  • Program Complete |IBRD 2019| 4-5 November 2019 | Leuven

Join us to get the latest updates on breaking innovations in rare diseases and orphan drugs from frontline speakers.

Who should attend? Junior & senior researchers, clinicians, pharma, policy makers, patient organisations active in the field of rare diseases or orphan drugs.

Please visit our website for more details or consult the program book. 

To register, please click here. Early bird registration until 1 September 2019.

Further questions? Please contact


PharmAbs in the press:

  • PharmAbs as bridge between academic research and industry (article in “De Morgen” 2018, 06, Dutch only)
  • PharmAbs as bridge between academic research and industry (article in “Economie werkt” 2017, 09, Dutch only)
  • EU EID PROFILE project in the picture (Read more)